ClinicalTrials.gg
Status unknownNCT04415320Updated Jun 4, 2020

X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

A Phase 2 interventional study of X-396(Ensartinib) in Lung Cancer, Nonsmall Cell and Brain Metastases, sponsored by Betta Pharmaceuticals Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by Betta Pharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2020), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Mar 2019, registered May 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 14 under way, 2 of them phase 3. ensartinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
13th of 20
37 · median 48
Started
2019
with 1 other
Phase 2
12 of 20
6 open now
Registered
8th of 20
by date
Lead sponsor
4 of 20
Betta Pharmaceuticals Co., Ltd.

Among the 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by planned enrollment, is one of 2 that started in 2019, is one of 12 in phase 2, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About ensartinib

ensartinib: first FDA approval 2024 (ENSACOVE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

To assess efficacy and safety of oral X-396 (Ensartinib) capsule in Chinese ALK-positive NSCLC patients with brain metastases, eligible patients will be enrolled with objective responses being primary outcome measures.

Read the detailed description

In this phase Ⅱ, open-label, single arm, multicenter study, efficacy and safety of oral X-396 capsule (Ensartinib) in 37 Chinese ALK-positive NSCLC patients with brain metastases will be assessed. Eligible patients will receive 225mg X-396 capsules once daily and objective responses of brain metastasis based on investigator assessment according to Response Assessment in Neuro-Oncology (RANO) are primary outcome measures.

03

Conditions studied

  • Lung Cancer, Nonsmall Cell
  • Brain Metastases

Keywords

  • NSCLC, Brain metastases, ALK mutations, X-396 (Ensartinib)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male, 18 years of age or older
  2. or cytologically confirmed locally advance or recurrent/ NSCLC that was positive for ALK mutations.
  3. Contrast-enhanced MRI or CT confirmed parenchymal with at least one (according to RANO and 1.1), which was not previously treated with radiotherapy.
  4. At most once treated with chemotherapy, which must have been completed at least 4 weeks before the initiation of study treatment. Any adverse events related to previous chemotherapy treatment have disappeared.
  5. A Performance Status score of at least 60.
  6. An expected survival time of at least 12 weeks.
  7. Adequate organ functions.
  8. Drug related toxicities has been relieved to grade 1 (based on v4.03), except for hair loss.
  9. Being willing and able to comply with scheduled visits, treatment plans, laboratory tests and other study procedures.
  10. Signed and dated .

Exclusion criteria

Exclusion Criteria:

  1. Currently under treatment of other systemic anti-cancer therapies.
  2. Evidence of active within last 5 years.
  3. Patients who participated in other clinical trials within last 4 weeks before the initiation of study treatment.
  4. Patients who received surgery or immunotherapy within last 4 weeks before the initiation of study treatment.
  5. Patients who need to receive drugs which are potent inhibitors or inducers within last 2 weeks before the initiation of study treatment and during the study.
  6. Patients who previously received organ transplantation or stem cell transplantation.
  7. Patients with cardiovascular diseases.
  8. Patients with active gastrointestinal diseases or other conditions that will interfere significantly with the absorption, distribution, metabolism or excretion of study medication.
  9. Patients with interstitial lung disease history or signs of active interstitial lung disease.
  10. Patients with known allergy or delayed reaction to study drug or its .
  11. Pregnant and lactating women.
  12. Patients with other illness or medical conditions potentially interfering with the study treatment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (estimated)

Study arms

  • Experimental
    X-396(Ensartinib) Capsule

    Drug: X-396(Ensartinib)

Interventions

  • All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.

06

What researchers measure

Primary outcomes

  1. Intracranial objective response rate (iORR) based on investigator assessment according to RNAO-BM.

    iORR per RANO-BM calculated as the proportion of patients with a best intracranial overall response defined as complete response (CR) or partial response (PR), based on investigator assessment.

    Time frame: 12 weeks

Secondary outcomes

  1. Disease control rate based on intracranial response (iDCR) according to RANO-BM.

    Defined as the percentage of patients who have achieved intracranial overall response of CR, PR and stable disease (SD), assessed by investigator.

    Time frame: 12 weeks

  2. Progression-free survival based on intracranial response (iPFS) according to RANO-BM

    Defined as time from first dose of X-396 capsule to intracranial disease progression or death due to any causes, assessed by investigator.

    Time frame: 36 months

  3. Time to progression based on intracranial response (iTTP) according to RANO-BM.

    Defined as time from first dose of X-396 capsule to intracranial disease progression, assessed by investigator.

    Time frame: 36 months

  4. Duration of response based on intracranial response (iDOR) according to RANO-BM.

    Defined as time from documentation of intracranial response (CR or PR) to intracranial disease progression or death, assessed by investigator.

    Time frame: 36 months

  5. Intracranial objective response rate (iORR) based on intracranial response according to RECIST 1.1.

    iORR per RECIST 1.1 calculated as the proportion of patients with a best intracranial overall response defined as complete response (CR) or partial response (PR), based on investigator assessment.

    Time frame: 12 weeks

  6. Disease control rate based on intracranial response (iDCR) according to RECIST 1.1

    Defined as the percentage of patients who have achieved intracranial overall response of CR, PR and stable disease (SD), assessed by investigator.

    Time frame: 12 weeks

  7. Progression-free survival based on intracranial response (iPFS) according to RECIST 1.1

    Defined as time from first dose of X-396 capsule to intracranial disease progression or death due to any causes, assessed by investigator.

    Time frame: 36 months

  8. Time to progression based on intracranial response (iTTP) according to RECIST 1.1

    Defined as time from first dose of X-396 capsule to intracranial disease progression, assessed by investigator.

    Time frame: 36 months

  9. Objective response rate (ORR) based on overall response according to RECIST 1.1.

    ORR per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response (CR) or partial response (PR), based on investigator assessment.

    Time frame: 12 weeks

  10. Disease control rate based on overall response (DCR) according to RECIST 1.1

    Defined as the percentage of patients who have achieved overall response of CR, PR and stable disease (SD), assessed by investigator.

    Time frame: 12 weeks

  11. Progression-free survival based on overall response (PFS) according to RECIST 1.1

    Defined as time from first dose of X-396 capsule to overall disease progression or death due to any causes, assessed by investigator.

    Time frame: 36 months

  12. Time to progression based on overall response (TTP) according to RECIST 1.1

    Defined as time from first dose of X-396 capsule to overall disease progression, assessed by investigator.

    Time frame: 36 months

  13. Overall survival (OS)

    Defined as time from first dose of X-396 to death due to any causes.

    Time frame: 36 months

  14. Incidence of patients experiencing adverse events.

    Incidence of adverse events occurred during the study (from the timeoint of signing a informed consent form to 30days after the end of trial) .

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
  • Fudan University Shanghai Cancer Center
    Shanghai, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Dec 2020, 21 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 21 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2020
First posted
Jun 4, 2020
StartActual
Mar 21, 2019
Primary completionEst.
Dec 2020
CompletionEst.
Jun 2021
Last update
Jun 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04415320
Collaborators
Fudan University
Responsible party
Sponsor
First posted
Jun 4, 2020
Start date
Mar 21, 2019
Primary completion
Dec 2020 (estimated)
Completion
Jun 2021 (estimated)
Last update
Jun 4, 2020

Study contacts

Jianhua Chang
Contact
changjianhua@163.com
8613916619284

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensartinib

Start the discussion